secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2025-05-20T23:59:59+00:00
Accession:  0001104659-25-050771
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics: lymphodepletion improves MT-601 cell expansion; enrollment surging
--------------------------------------------------------------------------------

- Phase 1 APOLLO study data: TCR sequencing shows MT-601 clones expanded/persisted at higher levels with lymphodepletion.
- Prior data (Dec 2024): 7/9 patients (78%) objective response, 4 complete responses (44.4%); no DLTs or ICANS.
- In first 5 months of 2025, enrolled and manufactured product for more patients than in all of 2024.
- Company expects clinical data readout from APOLLO study later this year.
- MT-601 targets lymphoma patients who relapsed after anti-CD19 CAR-T or for whom CAR-T is not an option.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925050771/0001104659-25-050771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925050771/tm2515620d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-050771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer